Home Overview Press Room Blog Publications For Students about us
Search

About Patents, Other Intellectual Property & Human Biotechnology


Human biotechnology is both constrained and catalyzed by intellectual property law, which regulates who can use certain information, ideas, and processes. Patents—one form of intellectual property—give the holder an exclusive right to produce and sell an invention.

While patents provide an incentive to inventors, they can also inhibit information flow. Their management has a tremendous impact on how biotechnologies are developed, and who benefits from them.

In the United States, the development of biotechnology has been dramatically influenced by two developments in 1980 that greatly increased the incentives for the commercialization of the life sciences. Congress passed the Bayh-Dole Act, which reformed how inventions from federally-funded research are managed. The same year, the Supreme Court ruled in Diamond v. Chakrabarty that living things, including genes, could be patented.



U.S. Proposes Effort to Analyze DNA from 1 Million Peopleby Toni Clarke and Sharon BegleyReutersJanuary 30th, 2015At the heart of the "precision medicine" initiative is the creation of a pool of people who would be studied to learn how genetic variants affect health and disease.
Stem Cell Clinics, FDA, and Giant, Unapproved For-Profit Human Experimentsby Paul KnoepflerKnoepfler Lab Stem Cell BlogJanuary 27th, 2015The argument by for-profit clinics for stem cell deregulation and weakening of the FDA’s role in regulating stem cell products is a direct challenge to our system of science-based medicine.
Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testingby Andrew PollackThe New York TimesJanuary 27th, 2015The company has settled or is in the process of settling patent-infringement lawsuits it filed against other companies that now offer such testing.
Obama to Request Research Funding for Treatments Tailored to Patients’ DNAby Robert PearThe New York TimesJanuary 24th, 2015President Obama will seek hundreds of millions of dollars for a new initiative to develop medical treatments tailored to genetic and other characteristics of individual patients.
European Court Opens Door for Stem Cell PatentingGenetic Engineering & Biotechnology NewsDecember 18th, 2014The European Court of Justice ruled that human embryonic stem cell patents could be allowed if organisms can't develop into human being.
Myriad Loses Appeals Court Bid to Block Breast Cancer Testsby Susan DeckerBloomberg BusinessweekDecember 17th, 2014Myriad Genetics can’t block competitors’ DNA tests to determine risk for breast and ovarian cancer after a US appeals court said three patents on the tests never should have been issued.
Have New Prenatal Tests Been Dangerously Oversold?by Beth DaleyNew England Center for Investigative ReportingDecember 12th, 2014Many prenatal testing companies promise more than they can deliver. Two studies show that results can be a false alarm half of the time.
Who Owns the Biggest Biotech Discovery of the Century?by Antonio RegaladoMIT Technology ReviewDecember 4th, 2014At stake are rights to an invention that may be the most important new genetic engineering technique since the beginning of the biotechnology age in the 1970s: the CRISPR system.
Evaluating California’s Stem Cell Experimentby David E. JensenSacramento BeeNovember 15th, 2014CIRM expects to be taking part in 10 early-stage clinical trials this year; however, no California-financed cures or therapies have reached the clinic and none are likely to do so for years.
Patently Absurd? Or Absurdly Patentable?by Pete ShanksBiopolitical TimesNovember 12th, 2014The US Supreme Court might agree to rule on the validity of stem-cell patents, and the Canadian courts are being asked to invalidate a patent on disease-linked genes.
Displaying 1-10 of 348  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760